S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

$0.98
+0.08 (+8.72%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$0.92
$1.10
50-Day Range
$0.90
$1.75
52-Week Range
$0.42
$2.05
Volume
1.48 million shs
Average Volume
1.81 million shs
Market Capitalization
$971.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
156.0% Upside
$2.50 Price Target
Short Interest
Healthy
0.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Adaptimmune Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.49) to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

Medical Sector

777th out of 908 stocks

Biological Products, Except Diagnostic Industry

134th out of 150 stocks

ADAP stock logo

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

ADAP Stock News Headlines

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 12.4%
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.16
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.9%
Peter W. Sonsini's Net Worth
ADAP Sep 2024 2.500 put
Adaptimmune Therapeutics Earnings Preview
Adaptimmune Therapeutics earnings: here's what Wall Street expects
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/22/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAP
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$4.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+156.0%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-113,870,000.00
Net Margins
-188.90%
Pretax Margin
-186.68%

Debt

Sales & Book Value

Annual Sales
$60.28 million
Book Value
$0.04 per share

Miscellaneous

Free Float
814,459,000
Market Cap
$971.04 million
Optionable
Optionable
Beta
2.39
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" ADAP shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price target for 2024?

1 brokerages have issued 12-month price targets for Adaptimmune Therapeutics' stock. Their ADAP share price targets range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 156.0% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2024?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of the year. Since then, ADAP stock has increased by 23.2% and is now trading at $0.9767.
View the best growth stocks for 2024 here
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) released its earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.12. The biotechnology company earned $0.23 million during the quarter, compared to the consensus estimate of $4.80 million. Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative trailing twelve-month return on equity of 155.39%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?
When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Key Client Fiduciary Advisors LLC (0.03%), JTC Employer Solutions Trustee Ltd (0.00%) and Columbia Advisory Partners LLC (0.00%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr.
View institutional ownership trends
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners